Levy Harkins Co Inc adds Intrexon Corp (XON) to its portfolio

Intrexon Corp (XON) : Levy Harkins Co Inc added new position in Intrexon Corp during the most recent quarter end. The investment management firm now holds 269,710 shares of Intrexon Corp which is valued at $8.1 Million , the company said in a statement filed on May 26, 2016 with the SEC.Intrexon Corp makes up approximately 3.44% of Levy Harkins Co Inc’s portfolio.

Other Hedge Funds, Including , Tlp Group added XON to its portfolio by purchasing 18,500 company shares during the most recent quarter which is valued at $518,925. Intrexon Corp makes up approx 0.31% of Tlp Group’s portfolio.Redmond Asset Management boosted its stake in XON in the latest quarter, The investment management firm added 206 additional shares and now holds a total of 9,542 shares of Intrexon Corp which is valued at $267,653. Intrexon Corp makes up approx 0.14% of Redmond Asset Management’s portfolio.Group One Trading reduced its stake in XON by selling 50,907 shares or 69.15% in the most recent quarter. The Hedge Fund company now holds 22,716 shares of XON which is valued at $553,135. Intrexon Corp makes up approx 0.06% of Group One Trading’s portfolio.Ironbridge Capital Management Lp boosted its stake in XON in the latest quarter, The investment management firm added 1,020 additional shares and now holds a total of 136,720 shares of Intrexon Corp which is valued at $3.3 Million. Intrexon Corp makes up approx 0.13% of Ironbridge Capital Management Lp’s portfolio.

Intrexon Corp closed down -0.8 points or -2.60% at $29.94 with 10,42,534 shares getting traded on Wednesday. Post opening the session at $30.56, the shares hit an intraday low of $29.85 and an intraday high of $30.9 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

On the company’s financial health, Intrexon Corp reported $-0.55 EPS for the quarter, missing the analyst consensus estimate by $ -0.39 based on the information available during the earnings call on May 10, 2016. Analyst had a consensus of $-0.16. The company had revenue of $43.40 million for the quarter, compared to analysts expectations of $46.25 million. The company’s revenue was up 28.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $+0.25 EPS.

Many Wall Street Analysts have commented on Intrexon Corp. Intrexon Corp was Initiated by JMP Securities to “Mkt Outperform” on May 3, 2016. Shares were Reiterated by Stifel on Mar 1, 2016 to “Buy” and Lowered the Price Target to $ 57 from a previous price target of $69 .Company shares were Reiterated by Mizuho on Mar 1, 2016 to “Neutral”, Firm has raised the Price Target to $ 29 from a previous price target of $28 .

Intrexon Corporation is engaged in the field of synthetic biology. The Company designs builds and regulates gene programs which are Deoxyribonucleic Acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount location and modification of biological molecules to control the function and output of living cells. The Company’s technologies include UltraVector RheoSwitch Therapeutic System Cell Systems Informatics Protein Engineering AttSite Recombinases LEAP (Laser Enabled Analysis and Processing) Antibody Discovery Neurospora & Agaricus Platforms Endometrial Regenerative Cells ActoBiotics Porcine Research Models and BeyondBio. The Company serves various markets including health food energy environment and consumer. The Company has five operating divisions: Human Therapeutics Synthetic Immunology Animal Sciences Agricultural Biotech and Industrial Products.

Leave a Reply

Intrexon Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Intrexon Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.